Skip to main content
Ocugen, Inc. logo

Ocugen, Inc. — Investor Relations & Filings

Ticker · OCGN ISIN · US43358V1098 LEI · 549300JVNUI9CXWJLR09 US Manufacturing
Open in API
Filings indexed 848 across all filing types
Latest filing 2017-07-11 Major Shareholding Noti…
Country US United States of America
Listing US OCGN

About Ocugen, Inc.

https://ocugen.com/

Ocugen, Inc. is a clinical-stage biotechnology company focused on discovering, developing, and commercializing novel gene therapies, cell therapies, and vaccines. The company's primary mission is to develop treatments for blindness diseases, leveraging its first-in-class modifier gene therapy platform. This platform represents a potential paradigm shift in treating inherited retinal diseases by aiming to address multiple genetic mutations with a single product. In addition to its focus on ocular health, Ocugen is also advancing a pipeline that includes vaccines for infectious diseases. The company is dedicated to addressing significant unmet medical needs and providing innovative therapeutic options for patients with debilitating conditions.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2017
Major Shareholding Notification
2017-07-11 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The text indicates that the filing announces the completion of enrollment in a Phase 3 clinical trial and includes a press release as an exhibit. There are no financial statements or detailed financial data presented in the document. The document is relatively short (2963 characters) and primarily serves as an announcement of an event rather than a detailed financial or management report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2017-06-27 English
8-K
Delisting Announcement Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated June 23, 2017, by Histogenics Corporation. The content describes the company's transfer of its stock listing from the NASDAQ Global Market to the NASDAQ Capital Market due to non-compliance with listing requirements. This is an official notice regarding a change in the company's stock exchange listing status. The document is short (3901 characters) and focuses on the delisting and transfer announcement. Therefore, it fits the category of a Delisting Announcement (DLST).
2017-06-26 English
FORM 4 SUBMISSION
Director's Dealing
2017-06-14 English
FORM 4 SUBMISSION
Director's Dealing
2017-06-14 English
FORM 4 SUBMISSION
Director's Dealing
2017-06-14 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.